Intravitreal Injections In Delhi

An intravitreal injection delivers medication directly into the vitreous cavity of the eye. It is one of the most commonly performed ophthalmic procedures worldwide — over 20 million are administered each year. The risk of serious complications like endophthalmitis is less than 1 in 1000 per injection when strict aseptic technique is followed. At Netram, we follow international aseptic protocols at every injection — no compromise.

Most patients report feeling pressure, not pain. The eye is thoroughly numbed with topical anaesthetic drops (proparacaine) before the injection. The needle entry through the sclera takes 2–3 seconds. You may see a brief flash of light or momentary darkening — this is normal. Many patients are surprised by how comfortable the procedure is. Mild foreign body sensation and redness may persist for 1–2 days after.

This depends entirely on your condition and your response to treatment. Wet AMD and DME are chronic conditions requiring long-term treatment — most patients need 3–5 loading injections followed by ongoing injections every 4–16 weeks depending on the drug and disease activity. We use Treat-and-Extend protocols to minimise the number of injections without compromising outcomes. Your OCT at every visit guides this decision objectively.

All four are anti-VEGF agents — they block the VEGF protein that drives abnormal blood vessel growth and leakage in the retina. Eylea (aflibercept) also blocks PlGF. Vabysmo (faricimab) additionally blocks Ang-2 — a second pathway — allowing the longest injection intervals (up to Q16W). Razumab and Accentrix are ranibizumab (biosimilar and branded respectively) — smaller molecules with good retinal penetration, approved for myopic CNV. Zybev is a bevacizumab biosimilar — the most affordable option. The choice depends on your diagnosis, prior treatment response, and budget. Dr. Anchal will recommend the right drug for your specific case.

Ozurdex is a biodegradable dexamethasone implant (0.7mg) inserted into the vitreous — it slowly releases steroid over 4–6 months. It works through an anti-inflammatory rather than anti-VEGF mechanism, making it the preferred choice for uveitic macular oedema, CRVO-related oedema, and patients who have not responded adequately to anti-VEGF therapy. It is also useful in patients on warfarin where frequent injections carry a higher risk. One Ozurdex injection may last 4–6 months, reducing overall visit frequency.

Yes — same-day bilateral injections are offered at Netram for conditions affecting both eyes, such as bilateral DME or AMD. International evidence shows bilateral same-day injections have a similar safety profile to unilateral injections when strict aseptic technique is used with separate instruments for each eye. This significantly reduces clinic visit burden, particularly for elderly patients or those travelling long distances.

Avoid rubbing the injected eye, dusty environments, swimming pools, and eye makeup for 48 hours. You may use artificial tears for mild surface irritation. There are generally no restrictions on reading, screens, or walking. Contact us immediately if you develop increasing pain, redness, sudden vision loss, or discharge — these may indicate endophthalmitis, which requires urgent treatment.

Anti-VEGF injections work for the duration their drug concentration remains above therapeutic levels in the vitreous — typically 4–8 weeks for most agents, up to 16 weeks for Vabysmo in suitable patients. The effect wears off as the drug is cleared, which is why regular monitoring and re-injection are necessary for chronic conditions like AMD and DME. The goal of Treat-and-Extend protocols is to find each patient's personalised injection interval — the longest interval at which disease remains inactive.

Our current pricing per injection: Zybev (bevacizumab biosimilar) — ₹15,000. Razumab (ranibizumab biosimilar) — ₹25,000. Accentrix (ranibizumab branded) — ₹35,000. Ozurdex (dexamethasone implant) — ₹45,000. Eylea (aflibercept) — ₹62,000. Vabysmo (faricimab) — ₹85,000. Cashless insurance facility is available for eligible patients. Please contact our team to understand your insurance coverage before your first injection.

For wet AMD and DME, most patients require long-term — sometimes lifelong — treatment to maintain vision. The good news is that with modern Treat-and-Extend protocols, many patients eventually reach injection intervals of 12–16 weeks, significantly reducing the treatment burden over time. Some patients with retinal vein occlusion or myopic CNV may achieve disease inactivity after a limited number of injections and not require further treatment. Your doctor will be honest about the expected treatment duration for your specific condition.